EP
STRO icon

Eversept Partners’s Sutro Biopharma STRO Stock Holding History

Eversept Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-73,161
Closed -$1.82M – 145
2026
Q1 		$1.82M Sell
73,161
-120,410
-62% -$2.18M 0.1% 91
2025
Q4 		$2.24M Sell
193,571
-35,560
-16% -$337K 0.11% 85
2025
Q3 		$1.99M Sell
229,131
-95
-0% -$808 0.14% 70
2025
Q2 		$1.64M Hold
229,226
– – 0.15% 55
2025
Q1 		$1.49M Buy
229,226
+159,785
+230% +$2.52M 0.15% 49
2024
Q4 		$1.28M Sell
69,441
-114,758
-62% -$3.5M 0.11% 60
2024
Q3 		$6.37M Buy
184,199
+10,286
+6% +$403K 0.44% 35
2024
Q2 		$5.1M Buy
173,913
+64,771
+59% +$2.56M 0.35% 42
2024
Q1 		$6.17M Buy
109,142
+3,496
+3% +$154K 0.41% 44
2023
Q4 		$4.53M Buy
105,646
+28,682
+37% +$910K 0.4% 40
2023
Q3 		$2.67M Buy
76,964
+2,173
+3% +$94.7K 0.23% 57
2023
Q2 		$3.48M Buy
+74,791
New +$3.72M 0.29% 48

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Eversept Partners's STRO Position: Q2 2026 in Review

Eversept Partners sold out of Sutro Biopharma (STRO) in Q2 2026, closing a stake of 73,161 shares — an estimated $1.82M sold.

Eversept Partners first reported a position in STRO in Q2 2023 and held it in 12 quarters. The position peaked at $6.37M in Q3 2024. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Eversept Partners reported no remaining Sutro Biopharma position as of Q2 2026 after selling out during the quarter.
  • Eversept Partners sold 73,161 Sutro Biopharma shares in Q2 2026, an estimated $1.82M.
  • Eversept Partners first reported a position in Sutro Biopharma in Q2 2023 and held it in 12 quarters.
  • Eversept Partners's Sutro Biopharma position peaked at $6.37M in Q3 2024.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.